579 related articles for article (PubMed ID: 34741755)
21. The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease?
Bajaj S; Jain S; Vyas P; Bawa S; Vohora D
Brain Res Bull; 2021 Sep; 174():305-322. PubMed ID: 34217798
[TBL] [Abstract][Full Text] [Related]
22. Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms.
Spradley JM; Guindon J; Hohmann AG
Pharmacol Res; 2010 Sep; 62(3):249-58. PubMed ID: 20416378
[TBL] [Abstract][Full Text] [Related]
23. Distinct Activity of Endocannabinoid-Hydrolyzing Enzymes MAGL and FAAH in Key Regions of Peripheral and Central Nervous System Implicated in Migraine.
Della Pietra A; Giniatullin R; Savinainen JR
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33530477
[TBL] [Abstract][Full Text] [Related]
24. Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition.
Papa A; Pasquini S; Contri C; Gemma S; Campiani G; Butini S; Varani K; Vincenzi F
Cells; 2022 Jan; 11(3):. PubMed ID: 35159280
[TBL] [Abstract][Full Text] [Related]
25. Endocannabinoid modulation by FAAH and monoacylglycerol lipase within the analgesic circuitry of the periaqueductal grey.
Lau BK; Drew GM; Mitchell VA; Vaughan CW
Br J Pharmacol; 2014 Dec; 171(23):5225-36. PubMed ID: 25041240
[TBL] [Abstract][Full Text] [Related]
26. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.
Petrosino S; Di Marzo V
Curr Opin Investig Drugs; 2010 Jan; 11(1):51-62. PubMed ID: 20047159
[TBL] [Abstract][Full Text] [Related]
27. New insights into endocannabinoid degradation and its therapeutic potential.
Bari M; Battista N; Fezza F; Gasperi V; Maccarrone M
Mini Rev Med Chem; 2006 Mar; 6(3):257-68. PubMed ID: 16515464
[TBL] [Abstract][Full Text] [Related]
28. Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms.
Kinsey SG; Long JZ; Cravatt BF; Lichtman AH
J Pain; 2010 Dec; 11(12):1420-8. PubMed ID: 20554481
[TBL] [Abstract][Full Text] [Related]
29. Inhibitors of Endocannabinoids' Enzymatic Degradation as a Potential Target of the Memory Disturbances in an Acute N-Methyl-D-Aspartate (NMDA) Receptor Hypofunction Model of Schizophrenia in Mice.
Kruk-Slomka M; Adamski B; Slomka T; Biala G
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511157
[TBL] [Abstract][Full Text] [Related]
30. Cannabinoid-Based Medicines and Multiple Sclerosis.
Manera C; Bertini S
Adv Exp Med Biol; 2021; 1264():111-129. PubMed ID: 33332007
[TBL] [Abstract][Full Text] [Related]
31. The FAAH inhibitor URB597 efficiently reduces tyrosine hydroxylase expression through CB₁- and FAAH-independent mechanisms.
Bosier B; Muccioli GG; Lambert DM
Br J Pharmacol; 2013 Jun; 169(4):794-807. PubMed ID: 22970888
[TBL] [Abstract][Full Text] [Related]
32. Inhibitors of the endocannabinoid-degrading enzymes, or how to increase endocannabinoid's activity by preventing their hydrolysis.
Feledziak M; Lambert DM; Marchand-Brynaert J; Muccioli GG
Recent Pat CNS Drug Discov; 2012 Apr; 7(1):49-70. PubMed ID: 22280341
[TBL] [Abstract][Full Text] [Related]
33. The endocannabinoid system: Novel targets for treating cancer induced bone pain.
Sun J; Zhou YQ; Chen SP; Wang XM; Xu BY; Li DY; Tian YK; Ye DW
Biomed Pharmacother; 2019 Dec; 120():109504. PubMed ID: 31627091
[TBL] [Abstract][Full Text] [Related]
34. Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development.
Hou L; Rong J; Haider A; Ogasawara D; Varlow C; Schafroth MA; Mu L; Gan J; Xu H; Fowler CJ; Zhang MR; Vasdev N; Ametamey S; Cravatt BF; Wang L; Liang SH
J Med Chem; 2021 Jan; 64(1):123-149. PubMed ID: 33379862
[TBL] [Abstract][Full Text] [Related]
35. Targeting the endocannabinoid system as a potential anticancer approach.
Schwarz R; Ramer R; Hinz B
Drug Metab Rev; 2018 Feb; 50(1):26-53. PubMed ID: 29390896
[TBL] [Abstract][Full Text] [Related]
36. Endocannabinoid contribution to Δ9-tetrahydrocannabinol discrimination in rodents.
Wiley JL; Walentiny DM; Wright MJ; Beardsley PM; Burston JJ; Poklis JL; Lichtman AH; Vann RE
Eur J Pharmacol; 2014 Aug; 737():97-105. PubMed ID: 24858366
[TBL] [Abstract][Full Text] [Related]
37. Characterization of the effects of reuptake and hydrolysis inhibition on interstitial endocannabinoid levels in the brain: an in vivo microdialysis study.
Wiskerke J; Irimia C; Cravatt BF; De Vries TJ; Schoffelmeer AN; Pattij T; Parsons LH
ACS Chem Neurosci; 2012 May; 3(5):407-17. PubMed ID: 22860210
[TBL] [Abstract][Full Text] [Related]
38. The potential of inhibitors of endocannabinoid metabolism as anxiolytic and antidepressive drugs--A practical view.
Fowler CJ
Eur Neuropsychopharmacol; 2015 Jun; 25(6):749-62. PubMed ID: 25791296
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate.
Vandevoorde S; Fowler CJ
Br J Pharmacol; 2005 Aug; 145(7):885-93. PubMed ID: 15895107
[TBL] [Abstract][Full Text] [Related]
40. Chemical probes of endocannabinoid metabolism.
Blankman JL; Cravatt BF
Pharmacol Rev; 2013 Apr; 65(2):849-71. PubMed ID: 23512546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
